|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.40 - 21.25|
|52 Week Range||11.30 - 27.86|
|PE Ratio (TTM)||-21.78|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
Q2 2017 Arena Pharmaceuticals Inc Earnings Call
Top-line results from this midstage study was the shot in the arm that Arena's shareholders needed.
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.